Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Bupivacaine vs Ropivacaine for Rebound Pain After Shoulder Arthroscopy
NCT07196631Phase 4Completed
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of liposomal bupivacaine (2 arms). Primary endpoint: Incidence of rebound pain up to 24 hours. Started Sep 2025; status: completed.
02
Drugs
liposomal bupivacaine
Beyond the preview
Go deeper on NCT07196631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07196631.